Topics

Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and More

09:47 EDT 11 Oct 2019 | Xconomy

Vir Biotechnology has joined the public markets, raising $142.9 million to support clinical tests of its infectious disease drugs. The San Francisco firm offered 7.1 million shares priced at $20 each, which was the low end of the $20 to $22 range that it had planned. Vir shares are expected to start trading later today […]

Original Article: Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and More

NEXT ARTICLE

More From BioPortfolio on "Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and More"

Quick Search

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...